Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer

NCT01242631 is registered in ClinicalTrials.gov with Hannover Medical School as lead sponsor.

NCT NCT01242631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01242631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer
Lead sponsor
Hannover Medical School
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2010
Completion date
March 31, 2014
Enrollment
25 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

germ cell cancer, testicular cancer